Insider Trading Alert - MU, OPK, AYI, DDR And CYBX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 21, 2014, 54 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $307.00 to $352,080,000.00.

Highlighted Stocks Traded by Insiders:

Micron Technology (MU) - FREE Research Report

Byrne Patrick J who is Director at Micron Technology sold 10,000 shares at $23.12 on Jan. 21, 2014. Following this transaction, the Director owned 111,053 shares meaning that the stake was reduced by 8.26% with the 10,000-share transaction.

Thorsen Steven L. JR who is VP of WW Sales &Corp Marketing at Micron Technology sold 60,000 shares at $23.02 on Jan. 21, 2014. Following this transaction, the VP of WW Sales &Corp Marketing owned 266,474 shares meaning that the stake was reduced by 18.38% with the 60,000-share transaction.

The shares most recently traded at $22.93, down $0.09, or 0.37% since the insider transaction. Historical insider transactions for Micron Technology go as follows:

  • 4-Week # shares sold: 256,492
  • 12-Week # shares sold: 911,364
  • 24-Week # shares sold: 1.3 million

The average volume for Micron Technology has been 39.6 million shares per day over the past 30 days. Micron Technology has a market cap of $23.7 billion and is part of the technology sector and electronics industry. Shares are up 2.9% year-to-date as of the close of trading on Tuesday.

Micron Technology, Inc., together with its subsidiaries, manufactures and markets semiconductor solutions worldwide. The company has a P/E ratio of 13.2. Currently there are 12 analysts that rate Micron Technology a buy, 3 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MU - FREE

TheStreet Quant Ratings rates Micron Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Micron Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 31,700 shares at $8.72 on Jan. 21, 2014. Following this transaction, the CEO & Chairman owned 137.9 million shares meaning that the stake was reduced by 0.02% with the 31,700-share transaction.

The shares most recently traded at $8.86, up $0.14, or 1.62% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.5 million shares per day over the past 30 days. Opko Health has a market cap of $3.6 billion and is part of the health care sector and health services industry. Shares are up 5.33% year-to-date as of the close of trading on Tuesday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acuity Brands (AYI) - FREE Research Report

Browning Peter C who is Director at Acuity Brands sold 927 shares at $132.04 on Jan. 21, 2014. Following this transaction, the Director owned 1,464 shares meaning that the stake was reduced by 38.77% with the 927-share transaction.

The shares most recently traded at $131.10, down $0.94, or 0.72% since the insider transaction. Historical insider transactions for Acuity Brands go as follows:

  • 4-Week # shares sold: 6,412
  • 12-Week # shares sold: 6,412
  • 24-Week # shares sold: 6,412

The average volume for Acuity Brands has been 337,300 shares per day over the past 30 days. Acuity Brands has a market cap of $5.7 billion and is part of the technology sector and electronics industry. Shares are up 19.58% year-to-date as of the close of trading on Tuesday.

Acuity Brands, Inc. designs, produces, and distributes lighting solutions, components, and services for commercial, institutional, industrial, infrastructure, and residential applications in North America and internationally. The stock currently has a dividend yield of 0.39%. The company has a P/E ratio of 39.1. Currently there is 1 analyst that rates Acuity Brands a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AYI - FREE

TheStreet Quant Ratings rates Acuity Brands as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Acuity Brands Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DDR (DDR) - FREE Research Report

Otto Alexander who is 10% Owner at DDR bought 240,319 shares at $15.54 on Jan. 21, 2014. Following this transaction, the 10% Owner owned 40.2 million shares meaning that the stake was reduced by 0.6% with the 240,319-share transaction.

The shares most recently traded at $15.72, up $0.18, or 1.17% since the insider transaction. Historical insider transactions for DDR go as follows:

  • 4-Week # shares bought: 106,547
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 106,547
  • 12-Week # shares sold: 3,600
  • 24-Week # shares bought: 106,547
  • 24-Week # shares sold: 12,249

The average volume for DDR has been 2.8 million shares per day over the past 30 days. DDR has a market cap of $5.6 billion and is part of the financial sector and real estate industry. Shares are up 1.95% year-to-date as of the close of trading on Tuesday.

DDR Corp. operates as a real estate investment trust (REIT) in the United States. The company engages in acquiring, developing, redeveloping, owning, leasing, and managing shopping centers, mini-malls, and lifestyle centers. The stock currently has a dividend yield of 3.98%. Currently there are 14 analysts that rate DDR a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DDR - FREE

TheStreet Quant Ratings rates DDR as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and poor profit margins. Get the full DDR Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cyberonics (CYBX) - FREE Research Report

Browne Gregory H who is SR VP Finance & CFO at Cyberonics sold 1,500 shares at $69.32 on Jan. 21, 2014. Following this transaction, the SR VP Finance & CFO owned 67,942 shares meaning that the stake was reduced by 2.16% with the 1,500-share transaction.

The shares most recently traded at $69.26, down $0.06, or 0.09% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 38,411
  • 24-Week # shares sold: 69,361

The average volume for Cyberonics has been 237,000 shares per day over the past 30 days. Cyberonics has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 5.12% year-to-date as of the close of trading on Tuesday.

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 40.5. Currently there are 7 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

General Electric Sells Distributed Power Unit to Advent for $3.25 Billion

General Electric Sells Distributed Power Unit to Advent for $3.25 Billion